NeuroMab™ Anti-CD32b Antibody, Clone NR123P
Functional antibody against Human CD32b
- Host Species:
- Human
- Species Reactivity:
- Human
- Applications:
- ELISA; WB; ADCC; Cyt; Block; In Vitro; In Vivo
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
SPECIFIC INQUIRY
inquiryDescription
Immunogen
Species Reactivity
Clonality
Host Species
Clone Number
Applications
Formulation
Preservatives
Concentration
Purification
Purity
Endotoxin Level
Low Endotoxin < 1 EU/mg
Shipping
Storage
Research Use Only
Figure 1 shows the binding of anti-CD32b antibodies to (Figure 1A) CD32bECDHis and (Figure 1B) CD32aECDHis measured by ELISA.
Figure 10 shows the binding of anti-CD32b antibodies to human peripheral blood leukocytes.
Figure 11 shows the binding of anti-CD32b antibody to CD32bECDHis in Western blot. Under reducing (lanes 1-6) and non-reducing conditions (9-12).
Figure 2 shows the binding of anti-CD32b antibodies to stably transfected IIA1.6 cells expressing full-length CD32b measured by flow cytometry.
Figure 3 shows the ability of anti-CD32b antibody to induce Daudi cell lysis by ADCC compared to HuMab-KLH
Figure 4 shows CD32b TR-FRET based binding competition data. Maximum TR-FRET fluorescence was determined in samples without unlabeled mAb (which did not compete with labeled mAb). Background fluorescence was measured in samples without CD32bECDHis and CD32aECDHis. The inhibition of a-KLH-AlexaFluor 647 binding to CD32bECDHis and CD32aECDHis was represented by IC50 values (Table 6). The data for antibody 026 illustrate antibodies 020, 022, 024, 028, 053 and 063.
Figure 5 shows the in vivo anti-tumor efficacy of anti-CD32b antibodies in a xenograft tumor model in SCID mice. Antibody was administered on day 0 (Figure 5A) or day 6 (Figure 5B) after tumor challenge; shown are mean counts per minute (cpm) values ± SEM for each treatment group.
Figure 6 shows the in vivo anti-tumor efficacy of anti-CD32b antibodies in a xenograft tumor model in SCID mice. Antibody was administered on day 6 (Figure 6A and 6B) or 14 days after tumor challenge (Figure 6C); data shown are mean tumor burden ± SEM for each group.
Figure 7 shows the ability of anti-CD32b antibodies to induce Daudi cell lysis by ADCC compared to HuMab-KLH. Data shown are mean ± SEM of triplicates.
Figure 8 shows the binding of anti-CD32b antibodies to membrane-bound CD32b1 expressed on IIA1.6 cells. Data shown are mean MFI ± stdev of three independent experiments.
Figure 9 shows the binding of anti-CD32b antibodies to mantle cell lymphoma cells.
Publications (0)
